Skip to main content

Table 2 Comparison of clinical and laboratory features between SOX30 hypermethylated and non-hypermethylated MDS patients

From: Identification and validation of SRY-box containing gene family member SOX30 methylation as a prognostic and predictive biomarker in myeloid malignancies

Patient’s features Total
(n = 104)
Non-hypermethylated
(n = 80)
Hypermethylated
(n = 24)
P value
Sex (male/female) 61/43 48/32 13/11 0.642
Median age, years (range) 62 (14–86) 63.5 (14–86) 67 (28–86) 0.689
Median WBC, ×109/L (range) 2.7 (0.6–82.4) 2.8 (0.6–82.4) 2.5 (1.1–44.4) 0.457
Median hemoglobin, g/L (range) 64 (26–140) 66 (36–140) 56 (26–107) 0.017
Median platelets, ×109/L (range) 60 (0–1176) 60 (0–754) 50 (10–1176) 0. 503
Median BM blasts, % (range) 5.0 (0.0–19.0) 5.0 (0.0–19.0) 11.0 (0.0–18.0) 0.006
WHO classifications (2018)     0.020
 MDS-SLD 10 9 (11%) 1 (4%)  
 MDS-RS 7 6 (8%) 1 (4%)  
 MDS-MLD 32 29 (36%) 3 (13%)  
 MDS-EB1 20 16 (20%) 4 (17%)  
 MDS-EB2 31 18 (23%) 13 (54%)  
 MDS with isolated del(5q) 3 1 (1%) 2 (8%)  
 MDS-U 1 1 (1%) 0 (0%)  
IPSS scores     0.021
 Low 11 9 (11%) 2 (8%)  
 Int-1 52 45 (56%) 7 (29%)  
 Int-2 22 16 (20%) 6 (25%)  
 High 12 5 (6%) 7 (29%)  
No data 7 5 (6%) 2 (8%)  
Gene mutations     
CEBPA (+/−) 3/91 3/71 0/20 > 0.999
IDH1/2 (+/−) 3/91 3/71 0/20 > 0.999
DNMT3A (+/−) 3/91 3/71 0/20 > 0.999
U2AF1 (+/−) 6/88 1/73 5/15 0.001
SRSF2 (+/−) 5/89 4/70 1/19 > 0.999
SF3B1 (+/−) 6/98 4/70 2/18 0.604
  1. WBC white blood cells, BM bone marrow, IPSS International Prognostic Scoring System